Our results were consistent with previous reports in thyroid and ovarian cancers in which miR-218 overexpression via lipid-based transfection downregulates Runx2 and inhibits cell proliferation, migration, and invasion in vitro [10, 12]. Here, RUNX2 is linked to ovarian cancer.